LONZA GROUP AG : Clarification on Biosimilar Activities 4-traders Basel, 05 October 2012 - Following several reports and rumors in the past few days in relation to the Biosimilar activities of the joint venture of Lonza and Teva, Lonza wants to clarify the current situation on rituximab. Given the changes to the ... |
